Exenatide more effective than insulinglargine in patients with type 2 diabetes

February 2011
Australian Journal of Pharmacy;Feb2011, Vol. 92 Issue 1089, p71
Case Study
The article presents a case study on the efficacy of exenatide on patients with type 2 diabetes. In the study, exenatide was compared with insulin gargine in adults with type 2 diabetes who had subtimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for three months longer. It highlights the importance of exenatide on patients who has a risk of hypoglycaemia, weight loss.


Related Articles

  • Hypoglycaemia exacts extra costs in Canada.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p7 

    The article discusses research on the association of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients in Canada, referencing a study by M. Bron and colleagues presented at the 70th Annual Scientific Sessions of the American Diabetes Association.

  • Intensive blood glucose control for type 2 diabetes: meta-analysis.  // Africa Health;Mar2012, Vol. 34 Issue 3, p59 

    The article reports on a meta-analysis of intensive blood glucose control for type 2 diabetes, which found that intensive control could not minimize all-cause mortality, however, can increase the risk of severe hypoglycaemia by about 30%.

  • Antibacterials/insulin detemir/omeprazole interaction.  // Reactions Weekly;8/1/2013, Issue 1463, p9 

    The article presents a case study of an 82-year-old man with hypoglycaemia, which developed during treatment with amoxicillin, clarithromycin, omeprazole and insulin detemir for type 2 diabetes.

  • PEDIATRIC MANAGEMENT PROBLEMS. Belkengren, Richard; Sapala, Shirley // Pediatric Nursing;Mar/Apr2000, Vol. 26 Issue 2, p182 

    Presents the case of a 14-year-old female with Type I diabetes. Social and family history; Factors that contributed to the occurrence of hypoglycemia; Treatment for the disease.

  • A Qualitative Study of Perceived Responsibility and Self-Blame in Type 2 Diabetes: Reflections of Physicians and Patients. Beverly, Elizabeth; Ritholz, Marilyn; Brooks, Kelly; Hultgren, Brittney; Lee, Yishan; Abrahamson, Martin; Weinger, Katie // JGIM: Journal of General Internal Medicine;Sep2012, Vol. 27 Issue 9, p1180 

    BACKGROUND: Despite new treatment therapies and the emphasis on patient activation, nearly 50 % of diabetes patients have hemoglobin A levels above target. Understanding the impact of unmet treatment goals on the physician-patient relationship is important for maintaining quality care in...

  • Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain. Hollmand, R. R. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p77 

    STUDY DESIGN Design: randomised controlled trial (Treating to Target in Type 2 Diabetes [4-T]). Allocation: concealed. Blinding: unblinded. STUDY QUESTION Setting: 58 centres in Ireland and the UK. Patients: 708 patients ⩾18 years of age (mean age 62 y, 64% men) who had type 2 diabetes for...

  • Efficacy of once-daily insulin.  // Primary Care Reports;Dec2009 Pharmacology Watch Supp, p1 

    The article discusses a new study on the use of once-a-day insulin to treat type 2 diabetes. The study was conducted by researchers from England, involving 708 patient who had suboptimal hemoglobin A1c. It was found that the basal insulin group presented lesser hypoglycemic episodes as well as...

  • Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. Ying Zhang; Yi-juan Xie; Dong-dong Meng; Hao-hang Zhang; Hui Chen; En Liu // Diabetology & Metabolic Syndrome;2014, Vol. 6 Issue 1, p1 

    Aim: Premixed insulin regimens are commonly used for the treatment of patients with type-2 diabetes mellitus (T2DM). However, limited data are available regarding next-step therapy options in cases where premixed insulin fails to provide adequate glycemic control. This 20-week observational...

  • IMPORTANCE OF METFORMIN WITH REPAGLINIDE IN THE TREATMENT OF TYPE II DIABETES MELLITUS: A DECADEL REVIEW. Ramanjireddy, T.; Dachinamoorthi, D.; Chandrasekhar, K. B. // Asian Journal of Pharmaceutical & Clinical Research;Jan-Mar2012 Supplement, p1 

    Objectives of this work is to summarize the consequent development of dosage form from clinical evidence to market and its combination to control the both, insulin deficiency and resistance, to achieve the minimal hypoglycemia, repaglinide shows that no cardiac and vascular effect, antioxidant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics